Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs (Q46915198)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 November 2007

Language	Label	Description	Also known as
English	Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs	scientific article published on 2 November 2007

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

1 reference

based on heuristic

inferred from title

author name string

Patricia N Banfor

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

Lee C Preusser

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

Thomas J Campbell

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

Kennan C Marsh

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

James S Polakowski

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

Glenn A Reinhart

6

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

Bryan F Cox

7

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

Ryan M Fryer

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

publication date

2 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

American Journal of Physiology Heart and Circulatory Physiology

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

294

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

H238-48

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Clinical pharmacology of levosimendan

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

L-type Ca2+ channels in fetal and adult ovine cerebral arteries

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Evidence-based use of levosimendan in different clinical settings

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Acute heart failure: inotropic agents and their clinical uses

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9-(3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8(4H,7H)-dione (A-325100), and the regulation of cardiovascular function in cons

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Role of endothelium and K+ channels in dobutamine-induced relaxation in rat mesenteric artery

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Effects of levosimendan and milrinone on oxygen consumption in isolated guinea-pig heart

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

The effects of levosimendan on [Ca2+]i in guinea-pig isolated ventricular myocytes

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

The role of Ca++-sensitizers for the treatment of heart failure

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Haemodynamic dose-efficacy of levosimendan in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Effects of levosimendan on myocardial contractility and Ca2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Noninvasive assessment of the ventricular relaxation time constant (tau) in humans by Doppler echocardiography.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Interaction of levosimendan with cardiac troponin C in the presence of cardiac troponin I peptides

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Effects of OR-1896, a metabolite of levosimendan, on force of contraction and Ca2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Cardiac electrophysiological effects of levosimendan, a new calcium sensitizer

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes.

1 reference

https://api.crossref.org/works/10.1152%2FAJPHEART.01181.2007

21 January 2018

Identifiers

10.1152/AJPHEART.01181.2007

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17982006

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46915198&oldid=2137669918"